AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 214 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $572,121 | -33.0% | 23,116 | -23.3% | 0.03% | -30.4% |
Q2 2023 | $853,678 | -3.5% | 30,144 | -21.8% | 0.05% | -16.4% |
Q1 2023 | $884,896 | +262.7% | 38,524 | +360.2% | 0.06% | +450.0% |
Q1 2022 | $244,000 | -20.3% | 8,372 | -10.0% | 0.01% | 0.0% |
Q4 2021 | $306,000 | -41.3% | 9,307 | -17.6% | 0.01% | -44.4% |
Q3 2021 | $521,000 | -10.2% | 11,289 | +7.2% | 0.02% | -5.3% |
Q2 2021 | $580,000 | +10.3% | 10,533 | +3.5% | 0.02% | -5.0% |
Q1 2021 | $526,000 | +3.5% | 10,177 | -13.1% | 0.02% | -9.1% |
Q4 2020 | $508,000 | +36.2% | 11,713 | +9.8% | 0.02% | +15.8% |
Q3 2020 | $373,000 | -48.1% | 10,665 | -20.6% | 0.02% | -52.5% |
Q2 2020 | $718,000 | +82.2% | 13,434 | +21.0% | 0.04% | +33.3% |
Q1 2020 | $394,000 | -45.5% | 11,099 | -26.7% | 0.03% | -3.2% |
Q4 2019 | $723,000 | +87.3% | 15,148 | +27.3% | 0.03% | +55.0% |
Q3 2019 | $386,000 | -38.5% | 11,899 | -5.4% | 0.02% | -33.3% |
Q2 2019 | $628,000 | -34.2% | 12,583 | -11.1% | 0.03% | -34.8% |
Q1 2019 | $955,000 | +49.0% | 14,155 | +1.9% | 0.05% | +15.0% |
Q4 2018 | $641,000 | -51.8% | 13,891 | -19.4% | 0.04% | -20.0% |
Q3 2018 | $1,330,000 | +2.6% | 17,241 | +12.0% | 0.05% | -3.8% |
Q2 2018 | $1,296,000 | -0.2% | 15,388 | -3.1% | 0.05% | 0.0% |
Q1 2018 | $1,298,000 | +49.2% | 15,875 | +4.3% | 0.05% | +52.9% |
Q4 2017 | $870,000 | -24.1% | 15,226 | -11.4% | 0.03% | -29.2% |
Q3 2017 | $1,147,000 | +39.5% | 17,182 | +7.6% | 0.05% | +29.7% |
Q2 2017 | $822,000 | +5.0% | 15,971 | +19.1% | 0.04% | +5.7% |
Q1 2017 | $783,000 | +29.9% | 13,413 | -7.1% | 0.04% | +25.0% |
Q4 2016 | $603,000 | -31.2% | 14,443 | -12.9% | 0.03% | -33.3% |
Q3 2016 | $876,000 | +45.5% | 16,580 | +15.3% | 0.04% | +44.8% |
Q2 2016 | $602,000 | -0.2% | 14,381 | -3.2% | 0.03% | -6.5% |
Q1 2016 | $603,000 | -49.8% | 14,860 | -19.6% | 0.03% | -45.6% |
Q4 2015 | $1,200,000 | -7.9% | 18,491 | +0.2% | 0.06% | -23.0% |
Q3 2015 | $1,303,000 | – | 18,454 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |